(RTTNews) - Phio Pharmaceuticals Corp. (PHIO) Friday announced that an independent Data Monitoring Committee or DMC completed a review of interim safety data in its Phase 1b clinical trial of PH-762 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback